Ascending single dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of NSA-789 administered orally to healthy subjects.
Phase of Trial: Phase I
Latest Information Update: 16 Feb 2009
At a glance
- Drugs NSA 789 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- 16 Feb 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 31 Mar 2008 Status changed from initiated to recruiting as reported by ClinicalTrials.gov
- 31 Mar 2008 New trial record.